Cargando…

Bevacizumab Added to Neoadjuvant Chemotherapy in HER2-Negative Non-Metastatic Breast Cancer

Detalles Bibliográficos
Autores principales:	Wan, Guoxing, Cao, Fengjun, Wang, Xuanbin, Sun, Xue
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ivyspring International Publisher 2019
Materias:	Letter To The Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6360292/ https://www.ncbi.nlm.nih.gov/pubmed/30719135 http://dx.doi.org/10.7150/jca.29461

Ejemplares similares

Predictive power of tertiary lymphoid structure signature for neoadjuvant chemotherapy response and immunotherapy benefit in HER2‐negative breast cancer
por: Bertucci, François, et al.
Publicado: (2023)

Protein Signature Predicts Response to Neoadjuvant Treatment With Chemotherapy and Bevacizumab in HER2-Negative Breast Cancers
por: Haugen, Mads H., et al.
Publicado: (2021)

Immune responses during neoadjuvant chemotherapy in triple negative breast cancer
por: Ghallab, Ahmed
Publicado: (2020)

Elevated YKL-40 expression is associated with a poor prognosis in breast cancer patients
por: Wan, Guoxing, et al.
Publicado: (2016)

Prediction of neoadjuvant chemotherapy response in breast cancer
por: Myllys, Maiju
Publicado: (2021)

Efficacy of bevacizumab combined with chemotherapy in the treatment of HER2-negative metastatic breast cancer: a network meta-analysis
por: Sun, Zhengwu, et al.
Publicado: (2020)

Comment on ‘The efficacy and toxicity of gemcitabine, carboplatin and bevacizumab in metastatic breast cancer‘
por: Kitchen, D, et al.
Publicado: (2013)

In Reply: Overall Survival of Resectable Metastatic Colon Cancer Treated With Neoadjuvant Chemotherapy or Adjuvant Chemotherapy in Non-academic Program
por: Hao, Zhonglin, et al.
Publicado: (2023)

Regarding “Neoadjuvant Versus Adjuvant Chemotherapy for Resectable Metastatic Colon Cancer in Non-academic and Academic Programs”
por: Su, I-Hsuan, et al.
Publicado: (2023)

Neoadjuvant Bevacizumab plus Chemotherapy versus Chemotherapy Alone to Treat Non-Metastatic Breast Cancer: A Meta-Analysis of Randomised Controlled Trials
por: Cao, Li, et al.
Publicado: (2015)

Assessing vascular effects of adding bevacizumab to neoadjuvant chemotherapy in osteosarcoma using DCE-MRI
por: Guo, J, et al.
Publicado: (2015)

Bevacizumab in the treatment of HER2-negative breast cancer
por: Lorusso, Vito
Publicado: (2008)

Bevacizumab in HER2-negative inflammatory breast cancer
por: Bertucci, François, et al.
Publicado: (2016)

Adverse events of bevacizumab for triple negative breast cancer and HER-2 negative metastatic breast cancer: A meta-analysis
por: Xun, Xueqiong, et al.
Publicado: (2023)

The impact of HER2-low status on response to neoadjuvant chemotherapy in clinically HER2-negative breast cancer
por: Wang, Wei, et al.
Publicado: (2022)

Optimal Choice of Neoadjuvant Chemotherapy for HER2-Negative Breast Cancer: Clinical Insights
por: Lucas, Mairi W, et al.
Publicado: (2022)

Bevacizumab based chemotherapy in first line treatment of HER2 negative metastatic breast cancer: results of a Moroccan observational institutional study
por: Boulaamane, Lamiaa, et al.
Publicado: (2012)

Bevacizumab plus preoperative chemotherapy in operable HER2 negative breast cancer: biomarkers and pathologic response
por: Sánchez-Rovira, P., et al.
Publicado: (2013)

Comment on ‘Nomogram to predict pathologic complete response in HER2-positive breast cancer treated with neoadjuvant systemic therapy'
por: Altundag, Kadri
Publicado: (2017)

CNA Landscape of HER2-Negative Breast Cancer in Anthracycline-Based Neoadjuvant Chemotherapy Regimens
por: Ibragimova, M. K., et al.
Publicado: (2023)

Stem Cells Inhibition by Bevacizumab in Combination with Neoadjuvant Chemotherapy for Breast Cancer
por: Sabatier, Renaud, et al.
Publicado: (2019)

Early and late outcomes of bevacizumab plus chemotherapy versus chemotherapy alone as a neoadjuvant treatment in HER2-negative nonmetastatic breast cancer: a meta-analysis of randomized controlled trials
por: Wei, Jinli, et al.
Publicado: (2018)

Neoadjuvant chemotherapy in technically unresectable adenocarcinoma of parotid
por: Dhumal, Sachin, et al.
Publicado: (2019)

Chemotherapy Options beyond the First Line in HER-Negative Metastatic Breast Cancer
por: Lorusso, Vito, et al.
Publicado: (2020)

Reply to ‘Comment on ‘Nomogram to predict pathologic complete response in HER2-positive breast cancer treated with neoadjuvant systemic therapy''
por: Fujii, Takeo, et al.
Publicado: (2017)

Disease-free and overall survival at 3.5 years for neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin and cyclophosphamide, for women with HER2 negative early breast cancer: ARTemis Trial
por: Earl, H. M., et al.
Publicado: (2017)

Neoadjuvant immune checkpoint inhibitor plus chemotherapy in rare tracheal tumors
por: Jiang, Ben‐Yuan, et al.
Publicado: (2021)

Neoadjuvant radiotherapy in triple-negative breast cancer: “the past should not steal the present or hide the future”
por: To, Nhu Hanh, et al.
Publicado: (2022)

Considering FOLFOXIRI plus bevacizumab for metastatic colorectal cancer with left-sided tumors
por: Sunakawa, Yu, et al.
Publicado: (2018)

Severe progressive dermatomyositis in a patient with metastatic ovarian cancer using bevacizumab
por: Menteşoğlu, Dilek, et al.
Publicado: (2022)

Neoadjuvant chemotherapy in pancreatic cancer: innovative, but still difficult
por: Boeck, S, et al.
Publicado: (2014)

Comment on ‘Diagnosis of pathological complete response to neoadjuvant chemotherapy in breast cancer by minimal invasive biopsy techniques'
por: Kuerer, Henry M, et al.
Publicado: (2016)

Continuation of bevacizumab and addition of hormone therapy following weekly paclitaxel therapy in HER2-negative metastatic breast cancer
por: Redondo, Andrés, et al.
Publicado: (2014)

Efficacy Evaluation of Bevacizumab Combined with Capecitabine in the Treatment of HER2-Negative Metastatic Breast Cancer: A Meta-Analysis
por: Hu, Yiyi, et al.
Publicado: (2023)

Negative genic switch of HER-2 in the primary tumor instead of the synchronous metastatic nodal lesions after neoadjuvant chemotherapy in a patient with primary HER2-positive breast cancer
por: Chen, Hao-ran, et al.
Publicado: (2017)

Administration of anti-HER2 antibody after nonmyeloablative allogeneic stem cell transplantation in metastatic breast cancer
por: Banna, G L, et al.
Publicado: (2006)

Reply: Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer
por: Feliu, J, et al.
Publicado: (2011)

Comment on ‘Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer’
por: Molina-Garrido, M J, et al.
Publicado: (2011)

Economic Evaluation of Adding Bevacizumab to Chemotherapy for Metastatic Colorectal Cancer (mCRC) Patients in Indonesia
por: Kristin, Erna, et al.
Publicado: (2021)

Reply to Comment on ‘Diagnosis of pathological complete response to neoadjuvant chemotherapy in breast cancer by minimal invasive biopsy techniques'
por: Heil, Joerg
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_o2d3elqn5gc1mcgimfobop9vml